June 01, 2006
AstraZeneca, Biovail enter into agreement for Zoladex
AstraZeneca and Biovail have entered into an agreement in which Biovail's specialty sales force will promote AstraZeneca's Zoladex (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the US and Puerto Rico. Financial terms of the deal were not disclosed. Biovail's 85-member specialty sales force currently promotes Zovirax cream and ointment to specialists and selected primary-care physicians in the US.